Orr Inbar

Sales & Marketing

In order to discuss the current unsettled landscape, and just how tariffs might affect patients, pharmaphorum spoke with Orr Inbar of QuantHealth.

Digital

Over 90% of experimental therapies that reach human trials fail to make it to market.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.